Therabody has launched CryoTherm Palm, a $399.99 thermoregulation device that uses palm cooling technology to lower core body temperature during high-intensity training. The portable, cordless device features dual cooling surfaces and delivers scientifically calibrated cooling to delay fatigue and sustain athletic output. CryoTherm Palm is the only palm cooling device validated through two controlled studies before launch. Research with Division I athletes at USC showed 28% more total work volume during resistance training, whilst a study with elite soccer players at IMG Academy found athletes felt 60% cooler and maintained 4.7% better sprint velocity across repeated efforts. England's national football team has incorporated the device into pre-tournament preparations. CryoTherm Palm is available now in the US, with international availability coming autumn 2026.

Therabody has appointed Dr. Dhaval Bhanusali as its first-ever Chief Dermatologist. The board-certified dermatologist and laser surgeon will shape product innovation, education and marketing whilst joining Therabody's Scientific Advisory Board. Dr. Bhanusali, known as Dr. B, will help drive the wellness technology company's clinical rigour and expand its reach within dermatology and skincare communities. His appointment comes as Therabody launches The G.O.A.T. campaign for its TheraFace Mask, supported by what the company claims is the largest clinical study in a commercially available LED mask. Dr. Bhanusali serves as Dermatologist-in-Residence for rhode by Hailey Bieber and is Co-Founder and Chief Medical Officer of Elm Biosciences. He previously built Skin Medicinals, described as the largest pharmatech platform in dermatology.

Therabody, a Los Angeles, CA-based wellness technology company, raised $165M in Growth Equity funding. The round was led by North Castle Partners, with participation from Kevin Hart’s HartBeat Ventures, LLC and Aaron Rodgers’ Rx3 Ventures